Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OCRELIZUMAB vs ODEVIXIBAT: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OCRELIZUMAB vs ODEVIXIBAT: Safety Overview

Metric OCRELIZUMAB ODEVIXIBAT
Total FAERS Reports 56,186 223
Deaths Reported 1,406 10
Death Rate 2.5% 4.5%
Hospitalizations 10,364 43
Average Patient Age 47.2 yrs 14.3 yrs
% Female Patients 72.5% 49.4%
FDA Approval Date N/A Jul 20, 2021
Manufacturer Genentech, Inc. Albireo Pharma, Inc.
Route INTRAVENOUS ORAL
Marketing Status Prescription Prescription